Neutropenia
Welcome,         Profile    Billing    Logout  
 413 Companies   276 Products   276 Products   144 Mechanisms of Action   555 Trials   44731 News 


«12345678910111213...626627»
  • ||||||||||  Prevymis (letermovir) / Merck (MSD)
    Trial completion, Trial completion date, Trial primary completion date:  Letermovir Use in Heart Transplant Recipients (clinicaltrials.gov) -  Apr 26, 2025   
    P4,  N=31, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jan 2025 | Trial primary completion date: Oct 2025 --> Jan 2025
  • ||||||||||  Neutrophils modulate the immune response to Cryptococcus neoformans (Exhibit Hall, Hawaii Convention Center; Board Number 1107) -  Apr 26, 2025 - Abstract #IMMUNOLOGY2025IMMUNOLOGY_1479;    
    Neutrophil depletion also decreases the Th2-type cytokine levels. Altogether, our data indicate that neutrophils play a role in modulating the cryptococcal immune response.
  • ||||||||||  Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Enrollment open:  Luspatercept for Clonal Cytopenias of Uncertain Significance (clinicaltrials.gov) -  Apr 25, 2025   
    P2,  N=50, Recruiting, 
    Abcam Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  A Case of Systemic Lupus Erythematosus Complicated by Secondary Evans Syndrome. (Pubmed Central) -  Apr 21, 2025   
    While secondary ES is associated with increased morbidity and mortality, any diagnosis of ES confers a poor prognosis. In this case report, we describe a young male patient diagnosed with systemic lupus erythematosus (SLE) and secondary ES that was complicated by multiple relapses and subsequent infections, bleeding events, and thrombotic events that ultimately led to the passing of the patient.
  • ||||||||||  Journal, Real-world evidence:  Application of dihydropyrimidine dehydrogenase deficiency testing for (Pubmed Central) -  Apr 18, 2025   
    The main toxicities observed in patients who received a DPYD genotype-based dose reduction were anemia, neutropenia, nausea and mucositis but events were primarily grade 1 or 2. Our experience confirms the technical feasibility and the usefulness of DPYD genotyping to reduce the risk of severe FPs toxicities.
  • ||||||||||  Review, Journal:  Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After (Pubmed Central) -  Apr 17, 2025   
    These guidelines, rather than a numerical correction of the absolute neutrophil count, suggest a holistic, patient-centered approach aiming at optimizing the management of chronic neutropenic patients and offering valuable and practical guidance to the hematologists for their daily clinical practice. These results suggest no evidence of a difference in efficacy between the two treatments and potentially more favorable safety profile for Lonca compared with Pola
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie
    Journal:  Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort. (Pubmed Central) -  Apr 16, 2025   
    We found that these two treatments were comparable in terms of overall efficacy, barring a higher rate of complete responses with Ven; safety profiles were different among the two groups as BTKi-treated patients had more cardiovascular toxicities (26% vs 4%) and Ven-treated subjects experienced more infectious events (82% vs 49%). Our data points out that Ven-based regimens are safe and effective in octogenarian patients with CLL despite their higher clinical complexity and comorbidity burden and should provide some basis for the design of prospective studies to further evaluate the optimal treatment regimen in this patient population.
  • ||||||||||  Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
    Enrollment closed:  Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) (clinicaltrials.gov) -  Apr 16, 2025   
    P2,  N=28, Active, not recruiting, 
    Our data points out that Ven-based regimens are safe and effective in octogenarian patients with CLL despite their higher clinical complexity and comorbidity burden and should provide some basis for the design of prospective studies to further evaluate the optimal treatment regimen in this patient population. Recruiting --> Active, not recruiting
  • ||||||||||  Journal:  Evaluation of the Management of Febrile Neutropenia in a Tertiary Care Center. (Pubmed Central) -  Apr 16, 2025   
    The overall management of FN was inappropriate in two thirds of the patient cases (67.9%) when evaluated according to the assessment criteria. The choice, dose, and duration of treatment needs improvement for optimization of therapy and improvement of patient outcomes.
  • ||||||||||  Journal:  Cant (Pubmed Central) -  Apr 16, 2025   
    The diagnose was made after a trio-whole genome sequencing identified a pathogenic missense variant of the gene ABCC9 (c.3460C > T;p. (Arg1154Trp)) causing Cant
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), MK-6598 / Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date, Monotherapy:  A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001) (clinicaltrials.gov) -  Apr 16, 2025   
    P1,  N=90, Active, not recruiting, 
    N=97 --> 9 | Trial completion date: Aug 2031 --> Mar 2025 | Recruiting --> Terminated; The study was terminated due to enrollment challenges. Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> May 2025 | Trial primary completion date: Dec 2027 --> May 2025
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    P2 data, Journal:  Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. (Pubmed Central) -  Apr 15, 2025   
    The combination therapy was manageable in terms of safety and toxicity, with a predictable safety profile. These findings suggest that lenvatinib and eribulin represent a promising treatment strategy for advanced, heavily pretreated solid tumors, warranting further exploration in larger clinical studies.
  • ||||||||||  Journal:  Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome. (Pubmed Central) -  Apr 15, 2025   
    Low Eif6 levels reduced Tp53 pathway activation but did not rescue neutropenia in Sbds-deficient zebrafish. Further studies elucidating the interplay between SBDS, EIF6, TP53, and cellular stress responses offer promising insights into SDS pathogenesis, somatic genetic rescue, and therapeutic strategies.